Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use PREZCOBIX safely and effectively. See full prescribing information for PREZCOBIX. PREZCOBIX® (darunavir and cobicistat) tablets, for oral use PREZCOBIX® PED (darunavir and cobicistat) tablets for oral suspension Initial U.S. Approval: 2015
Medication labelWhy this: Advisory · dailymed-prescription
PREZCOBIX and PREZCOBIX PED are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) in treatment-naïve and treatment-experienced adults and pediatric patients 3 years of age and older weighing at least 15 kg with no darunavir resistance-associated substitutions (V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, L89V) [see Use in Specific Populations (8.4) and Clinical Studies (14)].
- generic_name
- darunavir ethanolate and cobicistat
- product_names
- DARUNAVIR ETHANOLATE and COBICISTAT
- ndc
- 59676-575, 59676-577, 59676-578, 59676-575-30, 59676-578-30, 59676-577-30
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en